Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England

Journal of Viral Hepatitis

Volumn 20, Issue 9, 2013, Pages 638-644

  McPherson, S ^a   Valappil, M ^c   Moses, S E ^b   Eltringham, G ^c   Miller, C ^a   Baxter, K ^a   Chan, A ^d   Shafiq, K ^e   Saeed, A ^f   Qureshi, R ^f   Hudson, M ^a   Bassendine, M F ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d Newcastle Chinese Healthy Living Centre   (United Kingdom)

^e SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

case finding; dry blood spot testing; hepatitis B; hepatitis C; screening

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; ASIAN; BRITISH ASIAN; CASE FINDING; CHINA; CHINESE; DISEASE ACTIVITY; DRIED BLOOD SPOT TESTING; FEMALE; FOLLOW UP; HEALTH EDUCATION; HEPATITIS B; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; PAKISTAN; PREVALENCE; PRIORITY JOURNAL; UNITED KINGDOM; VIET NAM;

CASE FINDING; DRY BLOOD SPOT TESTING; HEPATITIS B; HEPATITIS C; SCREENING;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL LABORATORY TECHNIQUES; DESICCATION; ENGLAND; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SPECIMEN HANDLING; VIROLOGY;

EID: 84881476334     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12084     Document Type: Article

References (38)

1. Cooke GS, Main J, Thursz MR,. Treatment for hepatitis B. BMJ 2010; 340: b5429.
2. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50 (3): 661-662.
3. EASL. Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50 (2): 227-242.
4. McMahon BJ,. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 (Suppl 1): 3-8.
5. Bosch FX, Ribes J, Cleries R, Diaz M,. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9 (2): 191-211, v.
6. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS,. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34 (6): 1329-1339.
7. Liaw YF, Sung JJ, Chow WC, et al,. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351 (15): 1521-1531.
8. Zhang QQ, An X, Liu YH, et al,. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J. 2011; 8: 72.
9. Hatzakis A, Wait S, Bruix J, et al,. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18 (Suppl 1): 1-16.
10. Liang X, Bi S, Yang W, et al,. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27 (47): 6550-6557.
11. Liang XF, Chen YS, Wang XJ, et al,. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old: the report from Chinese Center for Disease Control and Prevention. Chin J Epidemiol 2005; 26: 655-658.
12. Kawsar M, Goh BT,. Hepatitis B virus infection among Chinese residents in the United Kingdom. Sex Transm Infect 2002; 78 (3): 166-168.
13. Liu J, Fan D,. Hepatitis B in China. Lancet 2007; 369: 1582-1583.
14. Lavanchy D,. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11 (2): 97-107.
15. Ahmed F, Foster GR,. Global hepatitis, migration and its impact on Western healthcare. Gut 2010; 59 (8): 1009-1011.
16. Chu JJ, Wormann T, Popp J, et al,. Changing epidemiology of Hepatitis B and migration-a comparison of six Northern and North-Western European countries. Eur J Public Health 2012; doi: 10.1093/eurpub/cks067.
17. Gay NJ, Hesketh LM, Osborne KP, Farrington CP, Morgan-Capner P, Miller E,. The prevalence of hepatitis B infection in adults in England and Wales. Epidemiol Infect 1999; 122 (1): 133-138.
18. ELPA. Report on Patient Self Help in Europe. Available at: http//www.hepsummit2010.org.uk. 2010 (accessed 20 March 2012).
19. Piorkowsky NY,. Europe's hepatitis challenge: defusing the "viral time bomb". J Hepatol 2009; 51 (6): 1068-1073.
20. CDC. Recommendations for the identification and public health management of persons with chronic hepatitis B. MMWR. 2008; 57 (8): 1-20.
21. Bedossa P, Bioulacsage P, Callard P, et al,. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 1: 15-20.
22. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 1996; 24 (2): 289-293.
23. WHO. Hepatitis B Fact Sheet 204. 2012. Available at: http://www.who.int/ mediacentre/factsheets/fs204/en/.
24. Cotler SJ, Cotler S, Xie H, Luc BJ, Layden TJ, Wong SS,. Characterizing hepatitis B stigma in Chinese immigrants. J Viral Hepat 2012; 19 (2): 147-152.
25. Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM,. Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening. Am J Public Health 2010; 100 (Suppl 1): S118-S124.
26. Hahné SJ, De Melker HE, Kretzschmar M, et al,. Prevalence of hepatitis B virus infection in The Netherlands in 1996 and 2007. Epidemiol Infect 2012; 140 (8): 1469-1480.
27. Uddin G, Shoeb D, Solaiman S, et al,. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat 2010; 17 (5): 327-335.
28. Veldhuijzen IK, Toy M, Hahne SJ, et al,. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010; 138 (2): 522-530.
29. Eckman MH, Kaiser TE, Sherman KE,. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis 2011; 52 (11): 1294-1306.
30. Post SE, Sodhi NK, Peng CH, Wan K, Pollack HJ,. A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. Health Aff (Millwood) 2011; 30 (2): 340-348.
31. Hutton DW, Tan D, So SK, Brandeau ML,. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147: 460-469.
32. Hahne S, Kretzschmar WT,. Migrants and hepatitis B: new strategies for secondary prevention needed. Eur J Public Health 2009; 19: 439.
33. Villa E, Cartolari R, Bellentani S, Rivasi P, Casolo G, Manenti F,. Hepatitis B virus markers on dried blood spots. A new tool for epidemiological research. J Clin Pathol 1981; 34 (7): 809-812.
34. Villar LM, de Oliveira JC, Cruz HM, Yoshida CF, Lampe E, Lewis-Ximenez LL,. Assessment of dried blood spot samples as a simple method for detection of hepatitis B virus markers. J Med Virol 2011; 83 (9): 1522-1529.
35. Brown BS, Klapper PE, Guiver M,. Development of diagnostic serological and molecular screening from diired blood spots for HCV, HIV, HBV and syphilis. J Clin Virol 2009; 1: S27-S28.
36. Hutse V, Verhaegen E, De Cock L, et al,. Oral fluid as a medium for the detection of hepatitis B surface antigen. J Med Virol 2005; 77 (1): 53-56.
37. Feinman SV, Krassnitski O, Sinclair JC, Wrobel DM, Berris B,. Hepatitis B surface antigen in saliva of HB-SAg carriers. J Lab Clin Med 1975; 85 (6): 1042-1048.
38. Wong WW, Woo G, Heathcote JE, Krahn M,. Cost effectiveness of screening immigrants for hepatitis B. Liver Int 2011; 31 (8): 1179-1190.